Nanoform: Disclosure of Major Holdings under Law 163/2024
Company Release
Nanoform Finland Plc
May 29, 2024
12.30 Finnish time / 11.30 Swedish time
Disclosure of Major Holdings under Law 163/2024
Nanoform Finland Plc ("Nanoform" or the "Company") has on May 28, 2024, received a notification from University of Helsinki Funds. The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the "Act"). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The notification has been made on the basis of the transition rules of the Act, and not an acquisition or disposal of shares.
Nanoform has one series of shares in which each share carries one vote. The percentage numbers indicate the shareholding on the date the Act entered into force on April 19, 2024. The aggregate number of shares at the entry into force of the Act was 78,445,164.
Total positions
of University of
Helsinki Funds
subject to the
notification
obligation:
% of % of shares Total Total number of
shares and voting of shares and
and rights both voting
voting through in % rights of issue
rights financial (7.A + (on April 19,
(total instruments 7.B) 2024)
of 7.A) (total of 7.B)
Resulting 5,61% - 5,61% 78,445,164
situation on the
date on
which threshold
was crossed or
reached
Position of - - -
previous
notification
(if applicable)
Notified
details of the
resulting
situation on
the date on
which the
threshold was
crossed or
reached:
A: Shares and
voting rights
Class/type of Number of % of shares and voting rights
sharesISIN shares and
code (if voting
possible) rights
Direct(SMA Indirect(SMA Direct(SMA 9:5) Indirect(SMA 9:6 and 9:7)
9:5) 9:6 and 9:7)
FI4000330972 4,397,719 - 5,61% -
- - - - -
- - - - -
SUBTOTAL A 4,397,719 5,61%
Information in
relation to
the person
subject to the
notification
obligation ☒
Person subject
to the
notification
obligation is
not controlled
by any natural
person or
legal entity
and does not
control any
other
undertaking(s)
holding
directly or
indirectly an
interest in
the
(underlying)
issuer.☐ Full
chain of
controlled
undertakings
through which
the voting
rights and/or
the
financial
instruments
are
effectively
held starting
with the
ultimate
controlling
natural person
or legal
entity:
Name % of shares % of shares and voting rights Total of both
and voting through financial instruments
rights
- - - -
- - - -
- - - -
- - - -
- - - -
The notification of major shareholdings is based on the law 163/2024, in accordance with which a shareholder of a First North company is required to notify certain major shareholdings within two months from the entry into force of the law, in the event that the holding of shares or votes on the entry into force of the law on April 19, 2024 was at least 5 % and it had not been made public prior. The numbers and percentages in the notification are current as of the date of the entry into force of the law 163/2024 which was April 19,2024.
Nanoform Finland Plc
For further information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com,+358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com,+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.